I can’t believe it’s true! Despite a 29% drop in Elevance Health’s stock, I still think it’s a strong buy!
Why am I so confident, you ask? Well, let’s break it down.
First off, let’s talk about that DCF price target of $549.60. That’s a 43% upside, my friends. Sounds pretty tempting, doesn’t it? I mean, who doesn’t love a good deal?
And then there’s ELV’s shift towards managed care. With all the industry tailwinds blowing in their favor, it’s like they’ve got a little extra push to keep them going. Sustainable margin expansion? Check. Revenue growth? Double check. It’s like they’re on a winning streak!
Now, I know what you’re thinking. What about those regulatory risks around Pharmacy Benefit Management? Well, let me tell you, CarelonRx has got it covered. Their diversified revenue streams and a healthy margin of safety in my modeling? It’s like having a safety net underneath a tightrope walker. Risky business? Not when you’ve got all your bases covered.
So, long story short, I’m still on Team Elevance Health. And you should be too!
What does this mean for me?
Well, as an investor, it means potential for some serious gains. With that 43% upside, you could be looking at a nice little boost to your portfolio. And who doesn’t want that, am I right? So, keep your eye on Elevance Health. This could be a game-changer.
How will this affect the world?
With Elevance Health in the spotlight, the healthcare industry could see some major shifts. Their focus on managed care and sustainable growth could set a new standard for the industry as a whole. Who knows, we could be looking at a whole new era of healthcare innovation!
